The information provided on EL7.AI is for educational and informational purposes only and does not constitute financial advice.

We use cookies to improve your experience and serve personalized ads.

By clicking Accept, you consent to our use of advertising cookies. See our Privacy Policy for details.

StocksMediumUpdated•Originally published 13 April 2026•Updated 14 April 2026•

1 min read

Thermo Fisher Partners with Singapore's PRECISE for Large-Scale Biobank Initiative

A man in a suit over a stock chart with 'Mondelez International' text, surrounded by chocolate, cocoa beans, factories, and shops.

Key Facts

1Thermo Fisher Scientific announced a strategic collaboration with Precision Health Research, Singapore (PRECISE) to advance the SG100K study.

about 2 months ago

Version History

1 additional source confirmed this story

Version 1about 2 months ago

What changed: Specified the 100,000 individual sample size, included Seer Inc. as a technical partner, and clarified the focus on discovering new therapeutic targets.

Thermo Fisher Scientific has expanded its strategic collaboration with Precision Health Research, Singapore (PRECISE) to advance the SG100K population biobank study, which targets a sample size of 100,000 Singaporean individuals. This partnership leverages advanced proteomics and AI-driven analytics to enhance disease detection and personalized care delivery. The technical workflow will now integrate Olink PEA platforms and Orbitrap Astral mass spectrometry with Seer’s Proteograph Product Suite to process large-scale biological data. A primary focus of the initiative is the discovery of novel therapeutic targets and biomarkers to drive medical innovation. This move reinforces Thermo Fisher's leadership in the high-growth healthcare technology sector and its commitment to long-term research. By combining these high-end tools, the project seeks to significantly improve precision medicine outcomes globally.